Abstract
Objectives
To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.
Methods
Patients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared.
Results
Of 59 patients included, 19 were defined as unresectable (32%), 33 borderline resectable (56%) and 7 resectable (12%) during the blind radiological evaluation after FOLFIRINOX. Once in a surgical setting, 27% were non-resectable, whereas 73% received surgical resection with a 70% R0 rate. Consequent sensitivity and specificity were 86% and 29%. At imaging review, significant decreases in longest tumour dimension were observed in both groups: from 32 mm (95% CI 15–55) to 21 (10–44) in group A and from 34 (18–70) to 26 (7–60) in group B, p < 0.05. However, a significant increase in tumour attenuation in all phases was only observed for R0 resected, from 52 HU (26–75) to 65 (35–92) in arterial phase (p < 0.001) and from 62 (36–96) to 78 (40–120) in the venous (p = 0.001).
Conclusion
After neoadjuvant FOLFIRINOX, CT predicted resectability with acceptable sensitivity but low specificity. The observation of increased tumour attenuation at CT scan after FOLFIRINOX treatment might represent a reliable predictor of R0 resection.
Key Points
• CT drives the assessment of PDAC resectability after FOLFIRINOX
• CT predicts resectability with acceptable sensitivity but low specificity
• Significant increase in tumour attenuation was only observed for R0 resected PDAC
• Tumour attenuation after FOLFIRINOX represents a reliable predictor of R0 resection
Similar content being viewed by others
Abbreviations
- AHPBA:
-
Americas Hepato-Pancreato-Biliary Association
- AJCC:
-
American Joint Committee on Cancer
- BR:
-
Borderline resectable
- CT:
-
Computed tomography
- DWI:
-
Diffusion-weighted imaging
- LA:
-
Locally advanced
- MR:
-
Magnetic resonance
- PDAC:
-
Pancreatic ductal adenocarcinoma
- RECIST:
-
Response Evaluation Criteria In Solid Tumours
References
American Cancer Society (2017) Key statistics for pancreatic cancer. https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. Accessed 8 Sept 2017
Hidalgo M (2010) Pancreatic Cancer. N Eng J Med 362:1605–1617
Konstantinidis IT, Wharshaw AL, Allen JN et al (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg 257:731–736
Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801–810
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 364:1817–1825
White RR, Hurwitz HI, Morse MA et al (2001) Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758–765
Landry J, Catalano PJ, Staley C et al (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587–592
Cai S, Hong TS, Goldberg SI et al (2013) Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer 119:4196–4204
Nitsche U, Wenzel P, Siveke JT et al (2015) Resectability after first line folfirinox in initially unresectable locally advanced pancreatic cancer: a single center experience. Ann Surg Oncol 22:s1212–s1220
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
Strobel O, Hank T, Hinz U et al (2017) Pancreatic cancer surgery: the new R-status counts. Ann Surg 265:565–573
Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846 discussion 46-8
Katz MH, Marsh R, Herman JM et al (2013) Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 20:2787–2795
Tempero MA, Arnoletti JP, Behrman SW et al (2012) Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703–713
Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733
Balachandran A, Bhosale PR, Charnsangavej C, Tamm EP (2014) Imaging of pancreatic neoplasms. Surg Oncol Clin N Am 23:751–788
Brennan DDD, Zamboni GA, Raptopoulos VD, Kruskal JB (2007) Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics 27:1653–1666
Lee ES, Lee JM (2014) Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol 20:7864–7877
Lu DSK, Reber HA, Krasny RM, Kadell BM, Sayre J (1997) Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 168:1439–1443
Chang J, Schomer D, Dragovich T (2015) Anatomical, physiological, and molecular imaging for pancreatic cancer: Current clinical use and future implications. Biomed Res Int 2015:269641
Cassinotto C, Cortade J, Belleannée G et al (2013) An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 82:589–593
Kim YE, Park MS, Hong HS et al (2009) Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Radiology 250:758–765
Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116
Katz MH, Fleming JB, Bhosale P et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749–5756
Cassinotto C, Mouries A, Lafourcade JP et al (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 273:108–116
Morgan DE, Waggoner CN, Canon CL et al (2010) Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR Am J Roentgenol 194:615–622
Compton CC, Henson DE (1997) Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med 121:1129–1136
Tempero MA, Malafa MP, Behrman SW et al (2014) Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12:1083–1093
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumor: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
National Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines, 2008
Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management and role of preoperative therapy. Ann Surg Oncol 13:1035–1046
Ferrone C, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17
Lee SS, Byun JH, Park BJ et al (2008) Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging 28:928–936
Kartalis N, Manikis GC, Loizou L et al (2016) Diffusion-weighted MR imaging of pancreatic cancer: A comparison of monoexponential, bi-exponential and non-Gaussian kurtosis models. Eur J Radiol Open 3:79–85
Braithwaite AC, Dale BM, Boll DT, Merkle EM (2009) Short and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 250:459–465
Niwa T, Ueno M, Ohkawa S et al (2009) Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 82:28–34
Cuneo KC, Chenevert TL, Ben-Josef E et al (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 7:644–649
Barral M, Taouli B, Guiu B et al (2015) Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology 274:45–63
Funding
The authors state that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Claudio Bassi, MD.
Conflict of interest
The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise.
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional review board approval was obtained.
Methodology
• retrospective
• diagnostic or prognostic study
• performed at one institution
Additional information
Giovanni Marchegiani and Valentina Todaro share the first authorship
Rights and permissions
About this article
Cite this article
Marchegiani, G., Todaro, V., Boninsegna, E. et al. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Eur Radiol 28, 4265–4273 (2018). https://doi.org/10.1007/s00330-018-5410-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-018-5410-6